Document is current
Any future updates will be listed below
-
Authors
Valencia, Tania
Yen, Laura Y.
Berman, Cindy
Vincent, Thomas
Davis, Scott
Varrone, Francesca https://orcid.org/0000-0003-1820-5955
Huang, Jianfeng
Mastroianni, Jessica
Carlson, Morgan
Owen, Tate
Kamel, Amin
Drygin, Denis
Kinberger, Garth A.
Gangwar, Shanti Pal https://orcid.org/0000-0003-1024-7608
Yelshanskaya, Maria V.
Ridley, John
Kirby, Robert
Alvarez, Jesus
Lakhia, Ronak https://orcid.org/0000-0002-4511-5341
Patel, Vishal https://orcid.org/0000-0003-2875-4659
Sobolevsky, Alexander I. https://orcid.org/0000-0001-5181-8644
Lee, Edmund C. https://orcid.org/0000-0001-5843-247X
-
Funding
Funding for this research was provided by:
Regulus Therapeutics
- License Information
-
More Information
Article History
Received: 30 October 2024
Accepted: 22 October 2025
First Online: 28 November 2025
Competing interests
: T.V., T.V., S.D., F.V., J.H., J.M., M.C., T.O., A.K., D.D., G.A.K. and E.C.L. are current or former employees of Regulus Therapeutics. C.B. is a consultant for Regulus Therapeutics. J.R. and R.K. are current or former employees of Metrion Biosciences. Both the V.P. and A.I.S. lab have sponsored research agreements with Regulus Therapeutics. V.P. serves as scientific consultant for Otsuka Pharmaceuticals, Maze Therapeutics, Travere Therapeutics, and Regulus Therapeutics. V.P. serves as the chair of the Scientific Advisory Panel for the PKD Foundation. A patent application related to the treatment of ADPKD was filed by The Board of Regents of The University of Texas System and Regulus Therapeutics, listing V.P. as an inventor. A patent application based on results disclosed herein was submitted by Regulus Therapeutics, listing D.D., G.A.K., and E.C.L. as inventors. The remaining authors declare no competing interests.
